Sarah Bhagat, PhD

Sarah Bhagat, PhD


Sarah joined Sofinnova as an Associate in 2017.  In 2020, she was promoted to Partner. She focuses on biopharmaceutical investments. Sarah currently serves as a Board Member for Inozyme and a Board Observer for Aeovian, Akouos, Antiva, Neurana, and NorthSea. Sarah additionally played a central role in Sofinnova’s investments in Apellis (APLS), Pionyr, and YmAbs (YMAB). She previously served as a Board Member for Promedior prior to its acquisition by Roche for up to $1.4B and Board Observer for NextCure (NXTC) and YmAbs (YMAB).

Prior to joining Sofinnova, Sarah was a postdoctoral fellow in neuroscience at Stanford University in the laboratories of Drs. Robert Malenka and Karl Deisseroth. As a graduate student at Yale, Sarah worked with Dr. Stephen Strittmatter, her thesis advisor and co-founder of Axerion Therapeutics, to identify novel targets and develop therapeutics for CNS injury and psychiatric disorders. Sarah was also a Venture Fellow for Canaan Partners. Prior to Yale, Sarah worked as a research assistant for The Rockefeller University. Before her time at Rockefeller, Sarah was a Clinical Research Coordinator at Massachusetts General Hospital in the Bipolar Clinic and Research Program.

Sarah received her Ph.D. in Neuroscience from Yale University, where she was a National Science Foundation Graduate Research Fellow. Sarah also holds a B.A. in Biological Psychology from Franklin & Marshall College. Sarah is also an alumna of Stanford’s Graduate School of Business Ignite Entrepreneurship and Innovation Program. Sarah is on the board of Stanford’s Neuroscience Translate Oversight Committee.

Active Companies

Alumni Companies